These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15967683)

  • 1. Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices.
    Bass AS; Tomaselli G; Bullingham R; Kinter LB
    J Pharmacol Toxicol Methods; 2005; 52(1):12-21. PubMed ID: 15967683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.
    Friedrichs GS; Patmore L; Bass A
    J Pharmacol Toxicol Methods; 2005; 52(1):6-11. PubMed ID: 15975833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ; Johnson DM; Weltens E; Lissens J
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
    Hoffmann P; Warner B
    J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
    Guo L; Guthrie H
    J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization.
    Tabo M; Kimura K; Ito S
    J Pharmacol Toxicol Methods; 2007; 55(3):254-61. PubMed ID: 17229580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of QT interval assessment in safety pharmacology.
    Lacroix P; Picard S
    Curr Protoc Pharmacol; 2006 Jul; Chapter 10():Unit10.7. PubMed ID: 22294169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
    Shah RR
    Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: the inseparable twins.
    Dumotier BM; Georgieva AV
    Cell Biol Toxicol; 2007 Jul; 23(4):293-302. PubMed ID: 17216548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
    Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
    Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
    Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
    J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA; Su Z; Martin RL; Cox BF
    Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].
    Kecskeméti V
    Neuropsychopharmacol Hung; 2004 Mar; 6(1):5-12. PubMed ID: 15125308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays.
    Trepakova ES; Koerner J; Pettit SD; Valentin JP;
    J Pharmacol Toxicol Methods; 2009; 60(1):45-50. PubMed ID: 19439186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
    Wible BA; Hawryluk P; Ficker E; Kuryshev YA; Kirsch G; Brown AM
    J Pharmacol Toxicol Methods; 2005; 52(1):136-45. PubMed ID: 15950494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
    Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
    J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.